Shares of ChemoCentryx Inc. (NASDAQ:CCXI) traded up 5.1% during mid-day trading on Monday . The stock traded as high as $4.77 and last traded at $4.77, with a volume of 57,097 shares trading hands. The stock had previously closed at $4.54.

Several analysts have issued reports on the stock. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The firm has a 50 day moving average price of $4.87 and a 200-day moving average price of $3.78. The stock’s market capitalization is $210.82 million.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. Equities research analysts predict that ChemoCentryx Inc. will post ($0.35) EPS for the current year.

In other news, Director Thomas A. Edwards acquired 25,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The shares were purchased at an average cost of $4.05 per share, for a total transaction of $101,250.00. Following the transaction, the director now directly owns 41,977 shares of the company’s stock, valued at $170,006.85. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Geoffrey M. Parker acquired 40,000 shares of the firm’s stock in a transaction dated Friday, May 13th. The shares were purchased at an average price of $4.03 per share, for a total transaction of $161,200.00. Following the completion of the transaction, the director now directly owns 13,514 shares in the company, valued at $54,461.42. The disclosure for this purchase can be found here.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.